secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apyx Medical Corp (APYX)
CIK:        0000719135
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001437749-25-015231
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apyx Medical Q1 revenue $9.4M (-8% YoY), Advanced Energy +6%, net loss narrows to $4.2M
--------------------------------------------------------------------------------

- Net loss attributable to stockholders $4.2M ($0.10/sh) vs $7.6M ($0.22/sh) prior year; adjusted EBITDA loss $2.4M vs $5.3M.
- Advanced Energy revenue up 6% to $7.9M; OEM down 45% to $1.5M. Total revenue $9.4M vs $10.2M.
- Reaffirmed FY2025 guidance: total revenue $47.6M-$49.0M, Advanced Energy $39.6M-$41.0M, OEM ~$8.0M.
- Planned launch of AYON Body Contouring System in H2 2025 pending FDA clearance; 510(k) submitted Q1 2025.
- Renuvion won 2025 NewBeauty Award for 'Best Minimally Invasive Skin Tightener'; Dolores Catania named Chief of Confidence.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/719135/000143774925015231/0001437749-25-015231-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/719135/000143774925015231/apyx20250316_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-015231

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer